The National Cancer Institute awarded $10 million to a multidisciplinary team led by Julio A. Aguirre-Ghiso to study breast cancer dormancy and relapse biology. The grant targets the biological processes that allow cancer cells to remain inactive and later resume growth. The research focus aligns with a pressing clinical challenge: preventing recurrence after initial response and long periods of minimal disease activity. By funding mechanistic work, the program aims to identify pathways that could be targeted to stop reactivation. For pipeline planners, the award reinforces NCI priority around late-stage control strategies and long-horizon translational research in breast cancer.